Profile data is unavailable for this security.
About the company
Aptamer Group plc is a United Kingdom-based company that develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications. The Company's Optimer platform delivers next-generation aptamer tools that are enabling researchers and developers across the spectrum of the life sciences. Its Optimer binders have been developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Its Aptamer Diagnostics division uses the Company's technology to support the development of diagnostic platforms, such as proteomics, lateral flow devices, biosensors and immunoassays, such as enzyme-linked immunosorbent assay (ELISA). Its Optimer platform supports a diverse portfolio of partners and technologies.
- Revenue in GBP (TTM)860.00k
- Net income in GBP-2.96m
- Incorporated2014
- Employees54.00
- LocationAptamer Group PLCWindmill House, Innovation WayYORK YO10 5BRUnited KingdomGBR
- Phone+44 19 0421 7404
- Websitehttps://www.aptamergroup.co.uk/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Deltex Medical Group plc | 1.78m | -1.29m |
Aptamer Group PLC | 860.00k | -2.96m |
Image Scan Holdings Plc | 2.56m | -11.06k |
Surgical Innovations Group Plc | 12.54m | -622.00k |
Feedback plc | 886.00k | -3.49m |
Myhealthchecked PLC | 9.39m | -1.04m |
Rua Life Sciences PLC | 2.19m | -1.44m |
Genincode PLC | 2.60m | -5.94m |
Proteome Sciences plc | 4.04m | -4.08m |
Cambridge Nutritional Sciences PLC | 9.77m | -328.00k |
Verici DX PLC | 3.36m | -3.73m |
Genedrive PLC | 272.00k | -5.00m |
Abingdon Health PLC | 6.14m | -1.27m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Interactive Investor Services Ltd.as of 31 Oct 2023 | 27.34m | 1.42% |
Lansdowne Partners (UK) LLPas of 20 Aug 2024 | 24.34m | 1.27% |